RU2020112490A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020112490A3 RU2020112490A3 RU2020112490A RU2020112490A RU2020112490A3 RU 2020112490 A3 RU2020112490 A3 RU 2020112490A3 RU 2020112490 A RU2020112490 A RU 2020112490A RU 2020112490 A RU2020112490 A RU 2020112490A RU 2020112490 A3 RU2020112490 A3 RU 2020112490A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558147P | 2017-09-13 | 2017-09-13 | |
| US62/558,147 | 2017-09-13 | ||
| PCT/US2018/050931 WO2019055689A1 (en) | 2017-09-13 | 2018-09-13 | HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020112490A RU2020112490A (ru) | 2021-10-13 |
| RU2020112490A3 true RU2020112490A3 (https=) | 2022-03-28 |
Family
ID=63714117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020112490A RU2020112490A (ru) | 2017-09-13 | 2018-09-13 | Антитела из тяжелых цепей, связывающиеся с эктоферментами |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200207867A1 (https=) |
| EP (1) | EP3681908A1 (https=) |
| JP (1) | JP2020533362A (https=) |
| KR (1) | KR20200044094A (https=) |
| CN (1) | CN111133007A (https=) |
| AU (1) | AU2018331421A1 (https=) |
| BR (1) | BR112020004846A2 (https=) |
| CA (1) | CA3075399A1 (https=) |
| IL (1) | IL273235A (https=) |
| MX (1) | MX2020002802A (https=) |
| RU (1) | RU2020112490A (https=) |
| SG (1) | SG11202002093TA (https=) |
| WO (1) | WO2019055689A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2021127489A1 (en) * | 2019-12-18 | 2021-06-24 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| CN114397453B (zh) * | 2022-03-25 | 2022-06-07 | 江苏美克医学技术有限公司 | 新型冠状病毒突变株的检测试剂盒及其应用 |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| US20100021473A1 (en) * | 2005-12-06 | 2010-01-28 | Domantis Limited | Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor |
| MX2008012843A (es) | 2006-04-05 | 2009-01-19 | Univ Rockefeller | Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados. |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TW201129384A (en) * | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| SG10201803288RA (en) * | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| CN110627907B (zh) * | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| JP6775422B2 (ja) * | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| CN107207594B (zh) * | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| MX389805B (es) * | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| MA43219A (fr) * | 2015-11-10 | 2018-09-19 | Univ Medical Center Hamburg Eppendorf | Polypeptides de liaison d'antigène dirigés contre cd38 |
-
2018
- 2018-09-13 KR KR1020207008904A patent/KR20200044094A/ko not_active Ceased
- 2018-09-13 SG SG11202002093TA patent/SG11202002093TA/en unknown
- 2018-09-13 CA CA3075399A patent/CA3075399A1/en active Pending
- 2018-09-13 JP JP2020514968A patent/JP2020533362A/ja active Pending
- 2018-09-13 EP EP18779951.5A patent/EP3681908A1/en not_active Withdrawn
- 2018-09-13 WO PCT/US2018/050931 patent/WO2019055689A1/en not_active Ceased
- 2018-09-13 US US16/646,970 patent/US20200207867A1/en not_active Abandoned
- 2018-09-13 CN CN201880059877.4A patent/CN111133007A/zh active Pending
- 2018-09-13 MX MX2020002802A patent/MX2020002802A/es unknown
- 2018-09-13 RU RU2020112490A patent/RU2020112490A/ru unknown
- 2018-09-13 BR BR112020004846-1A patent/BR112020004846A2/pt not_active IP Right Cessation
- 2018-09-13 AU AU2018331421A patent/AU2018331421A1/en not_active Abandoned
-
2020
- 2020-03-11 IL IL273235A patent/IL273235A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018331421A1 (en) | 2020-04-30 |
| BR112020004846A2 (pt) | 2020-09-15 |
| IL273235A (en) | 2020-04-30 |
| CA3075399A1 (en) | 2019-03-21 |
| RU2020112490A (ru) | 2021-10-13 |
| US20200207867A1 (en) | 2020-07-02 |
| SG11202002093TA (en) | 2020-04-29 |
| JP2020533362A (ja) | 2020-11-19 |
| KR20200044094A (ko) | 2020-04-28 |
| WO2019055689A1 (en) | 2019-03-21 |
| MX2020002802A (es) | 2020-10-12 |
| EP3681908A1 (en) | 2020-07-22 |
| CN111133007A (zh) | 2020-05-08 |
| AU2018331421A2 (en) | 2020-05-28 |